DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 188 filers reported holding DENALI THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 2.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $642 | -26.6% | 31,102 | +4.8% | 0.00% | -33.3% |
| Q2 2023 | $875 | +29.6% | 29,665 | +1.3% | 0.01% | +20.0% |
| Q1 2023 | $675 | -7.2% | 29,287 | +12.0% | 0.01% | 0.0% |
| Q4 2022 | $727 | -99.9% | 26,149 | -7.3% | 0.01% | -16.7% |
| Q3 2022 | $866,000 | +112.3% | 28,221 | +103.3% | 0.01% | +100.0% |
| Q2 2022 | $408,000 | -23.0% | 13,879 | -15.8% | 0.00% | 0.0% |
| Q1 2022 | $530,000 | -23.6% | 16,488 | +5.9% | 0.00% | 0.0% |
| Q4 2021 | $694,000 | +9.5% | 15,569 | +23.8% | 0.00% | 0.0% |
| Q3 2021 | $634,000 | -21.2% | 12,573 | +22.6% | 0.00% | -25.0% |
| Q2 2021 | $805,000 | +61.3% | 10,259 | +17.5% | 0.00% | +33.3% |
| Q1 2021 | $499,000 | -17.4% | 8,733 | +21.0% | 0.00% | -25.0% |
| Q4 2020 | $604,000 | – | 7,216 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
| Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
| Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
| Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
| MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
| Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
| PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
| HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |